Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
Silo Pharma, a developmental stage biopharmaceutical company, will attend a hybrid public meeting hosted by the FDA and Reagan-Udall Foundation on June 27, 2024. The event, titled “Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest,” will discuss ketamine's use for treating depression and chronic pain. CEO Eric Weisblum, along with a scientific advisor, will represent Silo Pharma. The company's lead program, SPC-15, is an intranasal treatment for PTSD and anxiety, licensed exclusively from Columbia University. Additionally, Silo is developing SP-26, a ketamine-based dissolvable implant for chronic pain and fibromyalgia.
- Silo Pharma will participate in an FDA meeting, enhancing visibility and credibility.
- The meeting will cover ketamine's emerging therapeutic uses, aligning with Silo’s focus areas.
- CEO Eric Weisblum’s attendance can foster new partnerships and collaborations.
- Silo's SPC-15 targets PTSD and anxiety, addressing underserved markets.
- Exclusive licensing from Columbia University for SPC-15 ensures market protection.
- SP-26 is designed as a controlled-release implant for chronic pain, offering innovative treatment solutions.
- The focus on psychedelic treatments aligns with increasing public and clinical interest.
- As a developmental stage company, Silo Pharma faces high risks and uncertainties.
- No FDA approvals yet for SPC-15 or SP-26, indicating a long pathway to market.
- Attending a meeting does not guarantee regulatory or market success.
- Potential financial strain from ongoing research and development costs.
- Reliance on exclusive licenses like from Columbia University can pose risks if partnerships dissolve.
- Emerging markets for psychedelic treatments are still uncertain and highly regulated.
Silo’s SP-26 currently in development utilizes ketamine as primary therapeutic agent
SARASOTA, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its planned attendance at a hybrid public meeting on June 27, 2024, hosted by the U.S. Food and Drug Administration (FDA) in partnership with the Reagan-Udall Foundation for the FDA. The in-person and virtual event, titled “Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest,” will explore the landscape for ketamine usage and increasing public interest in ketamine as a treatment for conditions such as depression and chronic pain.
CEO Eric Weisblum and a scientific advisor to Silo will attend the scheduled discussions and engage with speakers and attendees including clinicians, academic researchers, patients and patient advocates, professional organizations, and federal partners.
Silo Pharma’s novel drug candidates utilize ketamine as a primary therapeutic agent:
- Silo’s lead program, SPC-15, is formulated and delivered as an intranasal prophylactic treatment for PTSD and stress-induced anxiety disorder—underserved markets with few approved drugs. Silo exercised its option to license SPC-15 on an exclusive basis from Columbia University for development, manufacturing, and commercializing SPC-15 worldwide.
- SP-26 is a ketamine-based injectable dissolvable implant for the treatment of chronic pain and fibromyalgia. The subcutaneous implant is being designed to safely regulate dosage and time release of the pain-relieving treatment.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silo’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. For more information, visit www.silopharma.com and connect on social media at LinkedIn, X, and Facebook.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
When will Silo Pharma attend the FDA meeting?
What is the focus of the FDA meeting Silo Pharma is attending?
What is Silo Pharma’s lead program?
What is SP-26?
Who will represent Silo Pharma at the FDA meeting?
What conditions is Silo Pharma targeting with its drug candidates?
Has Silo Pharma received FDA approval for its treatments?
